ARRY 502

Drug Profile

ARRY 502

Alternative Names: ARRY502

Latest Information Update: 17 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Class Antiallergics
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Suspended Allergic asthma

Most Recent Events

  • 17 Oct 2014 Suspended - Phase-II for Allergic asthma in USA (PO)
  • 03 Mar 2014 Efficacy and adverse events data from a phase IIa trial in Allergic asthma presented at the American Academy of Allergy, Asthma and Immunology (AAAAI-2014)
  • 23 Jul 2013 Top-line efficacy & adverse events data from a phase IIa trial in Allergic asthma released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top